PT  - JOURNAL ARTICLE
AU  - Stamate, Daniel
AU  - Kim, Min
AU  - Proitsi, Petroula
AU  - Westwood, Sarah
AU  - Baird, Alison
AU  - Nevado-Holgado, Alejo
AU  - Hye, Abdul
AU  - Bos, Isabelle
AU  - Vos, Stephanie
AU  - Vandenberghe, Rik
AU  - Teunissen, Charlotte E.
AU  - Kate, Mara Ten
AU  - Scheltens, Philip
AU  - Gabel, Silvy
AU  - Meersmans, Karen
AU  - Blin, Olivier
AU  - Richardson, Jill
AU  - Roeck, Ellen De
AU  - Engelborghs, Sebastiaan
AU  - Sleegers, Kristel
AU  - Bordet, Régis
AU  - Rami, Lorena
AU  - Kettunen, Petronella
AU  - Tsolaki, Magda
AU  - Verhey, Frans
AU  - Alcolea, Daniel
AU  - Lléo, Alberto
AU  - Peyratout, Gwendoline
AU  - Tainta, Mikel
AU  - Johannsen, Peter
AU  - Freund-Levi, Yvonne
AU  - Frölich, Lutz
AU  - Dobricic, Valerija
AU  - Frisoni, Giovanni B
AU  - Molinuevo, José L
AU  - Wallin, Anders
AU  - Popp, Julius
AU  - Martinez-Lage, Pablo
AU  - Bertram, Lars
AU  - Blennow, Kaj
AU  - Zetterberg, Henrik
AU  - Streffer, Johannes
AU  - Visser, Pieter J
AU  - Lovestone, Simon
AU  - Legido-Quigley, Cristina
TI  - A metabolite-based machine learning approach to diagnose Alzheimer’s-type dementia in blood: Results from the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort
AID  - 10.1101/19007146
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19007146
4099  - http://medrxiv.org/content/early/2019/09/27/19007146.short
4100  - http://medrxiv.org/content/early/2019/09/27/19007146.full
AB  - INTRODUCTION Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer’s Disease (AD). Here we set out to test the performance of metabolites in blood to categorise AD when compared to CSF biomarkers.METHODS This study analysed samples from 242 cognitively normal (CN) people and 115 with AD-type dementia utilizing plasma metabolites (n=883). Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random Forest (RF) were used to differentiate AD from CN. These models were internally validated using Nested Cross Validation (NCV).RESULTS On the test data, DL produced the AUC of 0.85 (0.80-0.89), XGBoost produced 0.88 (0.86-0.89) and RF produced 0.85 (0.83-0.87). By comparison, CSF measures of amyloid, p-tau and t-tau (together with age and gender) produced with XGBoost the AUC values of 0.78, 0.83 and 0.87, respectively.DISCUSSION This study showed that plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers in a relatively small cohort. Further studies in independent cohorts are needed to validate whether this specific panel of blood metabolites can separate AD from controls, and how specific it is for AD as compared with other neurodegenerative disordersCompeting Interest StatementThe authors have declared no competing interest.Funding StatementIMI hasAuthor DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesOn request to the data repository’s